- News & Analysis
- Home
- Latest News
- Reports
- Podcast
- The CVC Funding Round Database
- The CVC Directory
- University
- Video
- Subscribe
- Newsletters
- Job Postings
- Events
Global University Venturing
C4 Therapeutics seals $170m round
The protein degradation-focused drug developer, a spinout from Dana-Farber Cancer Institute, received $150m in series B funding and $20m in venture debt.
Jun 17, 2020Goel moves into UToronto’s Covid-19 response
Vivek Goel will move into a coronavirus response-oriented advisory role having been University of Toronto vice-president for research, innovation and strategic initiatives since 2015.
Jun 17, 2020Wandelbots wins $30m
Wandelbots, which came out of Technical University of Dresden research, secured the funding as it publicly launched its robotics training software tool.
Jun 17, 2020Daily deal net: June 17, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Jun 17, 20204DMT materialises $75m series C round
4D Molecular Therapeutics secured the return of Berkeley Catalyst Fund for a series C round that follows plans for a $100m IPO announced in September 2019.
Jun 17, 2020CureVac gets a $339m kick from KfW
The Eli Lilly and Genmab-backed RNA drug developer is now valued at nearly $1.5bn following a decision to refocus on a coronavirus vaccine.
Jun 16, 2020Daily deal net: June 16, 2020
Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Jun 16, 2020Immvira reveals $58m series B round
Based on research from academic schools including Princeton, Chicago and Alabama at Birmingham, the oncolytic viral therapy developer has now received more than $80m to date.
Jun 16, 2020Kahoot cajoles $28m in private placement
The educational game portal, a spinout of Norwegian University of Science and Technology, pulled in $28m as investors also bought $62m of secondary shares.
Jun 16, 2020Verve swerves into $63m
GV, a corporate venturing subsidiary of internet and technology group Alphabet, has led a $63m series A2 round for Verve Therapeutics, a US-based developer of genomic heart disease drugs.
Jun 15, 2020Bit Bio whips up series A funding
University of Cambridge stem cell differentiation spinout Bit Bio secured $41.5m from investors including Arch Venture Partners to boost its overall funding to $50m.
Jun 15, 2020IQM Finland inspects $16.9m
The Aalto University and VTT quantum computer spinout has lined up a potential series A round with an initial $16.9m contribution from EIC Accelerator.
Jun 15, 2020Featured Content
University Venture Funds: The ListThe definitive list of university venture funds around the worldUniversity Venture Funds: The List
The definitive list of university venture funds around the world
Special ReportCorporate collaboration with universities: How to commercialise innovative researchSpecial Report
Corporate collaboration with universities: How to commercialise innovative research
Beyond the Breakthrough PodcastExplore the BTB podcast archive with the world's brightest minds in university innovation answering the question: how does research make it from a lab into the real world?Beyond the Breakthrough Podcast
Explore the BTB podcast archive with the world's brightest minds in university innovation answering the question: how does research make it from a lab into the real world?
About us
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
Navigation


